8-{2-[(2-戊基环丙基)甲基]环丙基}辛酸 - CAS号 28399-31-7

物化性质

沸点：

417.0±13.0 °C(Predicted)
密度：

0.968±0.06 g/cm3(Predicted)
溶解度：

二甲基亚砜：>2mg/mL

计算性质

辛醇/水分配系数(LogP)：

7.7
重原子数：

22
可旋转键数：

14
环数：

2.0
sp3杂化的碳原子比例：

0.95
拓扑面积：

37.3
氢给体数：

1
氢受体数：

2

安全信息

储存条件：

| 2-8℃ |

SDS

SDS：2e01acfbf43da91d102fdb90f767ebc1

查看

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : DCP-LA
CAS-No. : 28399-31-7

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No 1272/2008
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
The product does not need to be labelled in accordance with EC directives or respective national laws.
Other hazards - none

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Synonyms : 2-[(2-pentylcyclopropyl)methyl]cyclopropaneoctanoic acid
8-[2-(2-pentyl-cyclopropylmethyl)-cyclopropyl]-octanoic acid
Formula : C20H36O2
Molecular Weight : 308,50 g/mol

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Avoid
breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: 2 - 8 °C
Specific end uses
no data available

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: viscous
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

生物活性

DCP-LA (FR236924) 是一种亚油酸衍生物，能够选择性地激活 PKCε。

靶点：PKCε

上下游信息

上游原料

中文名称英文名称 CAS号化学式分子量

DCPLA甲酯 methyl 8-(2-((2-pentylcyclopropyl)methyl)cyclopropyl)octanoate 56687-67-3 C₂₁H₃₈O₂ 322.532
下游产品

中文名称英文名称 CAS号化学式分子量

—— tert-butyl 8-(2-((2-pentylcyclopropyl)methyl)cyclopropyl)octanoate —— C₂₄H₄₄O₂ 364.612

中文名称	英文名称	CAS号	化学式	分子量
DCPLA甲酯	methyl 8-(2-((2-pentylcyclopropyl)methyl)cyclopropyl)octanoate	56687-67-3	C₂₁H₃₈O₂	322.532

中文名称	英文名称	CAS号	化学式	分子量
——	tert-butyl 8-(2-((2-pentylcyclopropyl)methyl)cyclopropyl)octanoate	——	C₂₄H₄₄O₂	364.612

反应信息

作为反应物：

描述：

8-{2-[(2-戊基环丙基)甲基]环丙基}辛酸在咪唑、 sodium acetate 、 C.I.酸性橙108 、溶剂黄146 、三乙胺、 N,N'-二环己基碳二亚胺、 calcium chloride 、 phospholipase D 作用下，以乙醚、氯仿、水为溶剂，反应 17.0h，生成

参考文献：

名称：

脂质筏形成：多元不饱和磷脂的关键作用

摘要：

导致脂质筏形成的力量了解甚少。迄今为止，大多数注意力都集中在胆固醇和高熔点脂质之间的有吸引力的相互作用上。排斥力很少受到关注。在这里，我们表明，胆固醇的可交换模拟物与液体无序双层中低熔点磷脂的可交换模拟物之间的排斥性相互作用比同一种固醇和高熔点磷脂的可交换模拟物之间的吸引力要强得多。在液体有序双层中。我们得出的结论是，多不饱和磷脂已被广泛视为脂质筏形成的主要参与者。该知识应引起人们对于控制多不饱和磷脂水平以使细胞膜正常发挥功能的兴趣。

DOI：

10.1002/anie.201611367
作为产物：

描述：

亚油酸甲酯在甲醇、 diethylzinc 、 lithium hydroxide 作用下，以 1,4-二氧六环、正己烷、二氯甲烷为溶剂，反应 3.0h，生成 8-{2-[(2-戊基环丙基)甲基]环丙基}辛酸

参考文献：

名称：

[EN] PKC ACTIVATORS AND COMBINATIONS THEREOF
[FR] ACTIVATEURS DE PKC ET DES COMBINAISONS DE CEUX-CI

摘要：

本公开涉及PKC激活剂及其组合物。本公开进一步涉及其组成物、试剂盒、用途和方法。

公开号：

WO2013071282A1

点击查看最新优质反应信息

文献信息

[EN] ESTERS OF DCPLA AND METHODS OF TREATMENT USING THE SAME<br/>[FR] ESTERS DE DCPLA ET MÉTHODES DE TRAITEMENT LES UTILISANT

申请人：BRNI NEUROSCIENCES INST

公开号：WO2013071281A1

公开（公告）日：2013-05-16

The present disclosure relates to esters of 8-[2-(2-pentyl- cyclopropylmethyl)cyclopropyl]-octanoic acid ("DCPLA"). The disclosure further relates to compositions, kits, and methods for treatment using the esters.

本公开涉及8-[2-(2-戊基-环丙基甲基)环丙基]-辛酸酯（"DCPLA"）的酯类化合物。该公开还涉及使用这些酯类化合物进行治疗的组合物、试剂盒和方法。
PKC activators and combinations thereof

申请人：Cognitive Research Enterprises, Inc.

公开号：US10821079B2

公开（公告）日：2020-11-03

The present disclosure relates to PKC activators and combinations thereof. The disclosure further relates to compositions, kits, uses, and methods thereof.

本公开涉及PKC激活剂及其组合物。该公开进一步涉及这些组合物的组成、试剂盒、用途和方法。
[EN] IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY<br/>[FR] LIPIDES IONISABLES POUR L'ADMINISTRATION D'ACIDES NUCLÉIQUES

申请人：PREC NANOSYSTEMS INC

公开号：WO2021000041A1

公开（公告）日：2021-01-07

The present document describes compounds, or pharmaceutically acceptable salt thereof, of a core formula (I) Wherein R1 includes an amino group. These compounds are particularly useful in the formulation and in vivo and ex vivo delivery of nucleic acid and protein therapeutics for preparing and implementing T cell transfection, gene editing, cancer therapies, cancer prophylactics, and in the preparation of vaccines.

本文件描述了核心公式（I）的化合物或其药用可接受盐，其中R1包括氨基团。这些化合物在核酸和蛋白治疗剂的制剂、体内和体外递送中特别有用，用于制备和实施T细胞转染、基因编辑、癌症治疗、癌症预防以及疫苗的制备。
[EN] HALOGENATED ESTERS OF CYCLOPROPANATED UNSATURATED FATTY ACIDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] ESTERS HALOGÉNÉS D'ACIDES GRAS INSATURÉS CYCLOPROPANÉS POUR UTILISATION DANS LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES

申请人：BRNI NEUROSCIENCES INST

公开号：WO2015058191A1

公开（公告）日：2015-04-23

The present disclosure describes novel PKC-ε activators chosen from halogenated esters of unsaturated fatty acids and derivatives thereof, including halogenated esters of both polyunsaturated and monunsaturated fatty acids and derivatives thereof. The disclosure further relates to compositions, kits, and methods for treatment using the halogenated esters.

本公开描述了从卤代酯类不饱和脂肪酸及其衍生物中选择的新型PKC-ε激活剂，包括多不饱和脂肪酸和单不饱和脂肪酸的卤代酯及其衍生物。该公开还涉及使用这些卤代酯的组合物、试剂盒和治疗方法。
[EN] CARBOXYLIC ACID COMPOUND HAVING CYCLOPROPANE RING<br/>[FR] COMPOSE D'ACIDE CARBOXYLIQUE AYANT UN CYCLE DE CYCLOPROPANE

申请人：FUJISAWA PHARMACEUTICAL CO

公开号：WO2002050013A1

公开（公告）日：2002-06-27

A carboxylic acid compound having cyclopropane ring(s) of the formula (I): wherein R is alkyl or alkenyl optionally having one or more 1,2-cyclopropylene in a carbon chain and/or optionally having cyclopropyl at the end of a chain,X is a single bond or alkylene, wherein the total number of carbon less the number of cyclopropane ring is 10-25, and a pharmaceutically acceptable salt thereof are provided. The compound (I) shows an LTP-like potentiation of synaptic transmission, allows slow metabolism in the living body, shows a stable LTP-like potentiation of synaptic transmission, and is useful as an agent for LTP-like potentiation of synaptic transmission, a cognition-enhancing drug or an agent for the prophylaxis and treatment of dementia, a learning and memory disorder and a neurotransmitter release disorder.

提供一种具有环丙烷环的羧酸化合物的公式（I）：其中R是烷基或烯基，可选地具有一个或多个1,2-环丙烯基在碳链中和/或在链的末端可选地具有环丙基，X是单键或烷基，其中碳数减去环丙烷环的数量为10-25，并提供其药学上可接受的盐。化合物（I）表现出类似LTP的突触传递增强作用，可以在活体内缓慢代谢，表现出稳定的类似LTP的突触传递增强作用，并且可用作LTP样突触传递增强剂、增强认知药物或预防和治疗痴呆、学习和记忆障碍以及神经递质释放障碍的药剂。

8-{2-[(2-戊基环丙基)甲基]环丙基}辛酸 | 28399-31-7

分子结构分类